Following our call to join in the discussion over the suitability of implementing a reporting checklist for bio–nano papers, the community responds.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Measurements of heterogeneity in proteomics analysis of the nanoparticle protein corona across core facilities
Nature Communications Open Access 03 November 2022
-
Importance of Standardizing Analytical Characterization Methodology for Improved Reliability of the Nanomedicine Literature
Nano-Micro Letters Open Access 20 August 2022
-
Too advanced for assessment? Advanced materials, nanomedicine and the environment
Environmental Sciences Europe Open Access 16 August 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
Change history
29 July 2019
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
09 July 2019
An amendment to this paper has been published and can be accessed via a link at the top of the paper
References
Wilhelm, S. et al. Nat. Rev. Mater. 1, 16014 (2016).
Leong, H. S. et al. Nat. Protoc. 5, 1406–1417 (2010).
Townson, J. L. et al. J. Am. Chem. Soc. 135, 16030–16033 (2013).
Dogra, P. et al. Nat. Commun. 9, 4551 (2018).
Cho, C.-F., Ablack, A., Leong, H.-S., Zijlstra, A. & Lewis, J. J. Vis. Exp. https://doi.org/10.3791/2808 (2011).
Durfee, P. N. et al. ACS Nano 10, 8325–8345 (2016).
FDA’s Approach to Regulation of Nanotechnology Products (FDA, 2018); https://www.fda.gov/scienceresearch/specialtopics/nanotechnology/ucm301114.htm
Swierczewska, M., Crist, R. M. & McNeil, S. E. Methods Mol. Biol. 1682, 3–16 (2018).
Crist, R. M. et al. Integr. Biol. 5, 66–73 (2013).
Gioria, S. et al. Nanomedicine https://doi.org/10.2217/nnm-2017-0338 (2018).
Caputo, F. et al. J. Control. Release 299, 31–43 (2019).
Prina-Mello, A. in Handbook of Nanomaterials for Cancer Theranostics (ed. Conde, J.) Ch. 17 (Elsevier, 2018).
Adiseshaiah, P. P. & Stern, S. T. Methods Mol. Biol. 1682, 241–253 (2018).
Nat. Nanotechnol. 13, 765 (2018).
Faria, M. et al. Nat. Nanotechnol. 13, 777–785 (2018).
Bouwmeester, H. et al. Nanotoxicology 5, 1–11 (2011).
Nat. Nanotechnol. 7, 545 (2012).
Pettitt, M. E. & Lead, J. R. Environ. Int. 52, 41–50 (2013).
Nat. Nanotechnol. 8, 69 (2013).
Schrurs, F. & Lison, D. Nat. Nanotechnol. 7, 546–548 (2012).
Nel, A. E. et al. ACS Nano 9, 5627–5630 (2015).
Zhang, H. et al. ACS Nano 6, 4349–4368 (2012).
Li, R. et al. ACS Nano 8, 1771–1783 (2014).
Li, R. et al. ACS Nano 12, 1390–1402 (2018).
Liu, X. et al. J. Clin. Invest. 127, 2007–2018 (2017).
“Definitions in Biomaterials” Conference Attracts World Experts to Chengdu, China (Society for Biomaterials, 7 January 2018); https://www.biomaterials.org/sites/default/files/docs/2018/biomaterials_definitions_conference_press_release.pdf
Clotilde, T. et al. J. Extracell. Vesicles 7, 1535750 (2018).
EV-TRACK Consortium. Nat. Methods 14, 228–232 (2017).
Acknowledgements
Kimberly S. Butler, Hon S. Leong and C. Jeffrey Brinker: Sandia National Laboratories is a multi-mission laboratory managed and operated by National Technology and Engineering Solutions of Sandia, LLC, a wholly owned subsidiary of Honeywell International, Inc., for the US Department of Energy’s National Nuclear Security Administration under contract DENA0003525. Any subjective views or opinions that might be expressed in the paper do not necessarily represent the views of the US Department of Energy or the US government.
Adriele Prina-Mello, Ruth Schmid, Peter Wick, Fanny Caputo, Patrick Boisseau, Rachael M. Crist and Scott E. McNeil: the view expressed in this Correspondence is reflective of the European Nanomedicine Characterisation Laboratory (EUNCL EC-H2020 ref. 654190) and the REFINE consortium (REFINE EC-H2020 ref. 761104). The work of authors Rachael M. Crist and Scott E. McNeil has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under contract no. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US government.
Author information
Authors and Affiliations
Corresponding author
Supplementary Information
Rights and permissions
About this article
Cite this article
Leong, H.S., Butler, K.S., Brinker, C.J. et al. On the issue of transparency and reproducibility in nanomedicine. Nat. Nanotechnol. 14, 629–635 (2019). https://doi.org/10.1038/s41565-019-0496-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41565-019-0496-9
This article is cited by
-
Too advanced for assessment? Advanced materials, nanomedicine and the environment
Environmental Sciences Europe (2022)
-
Characterization of nanoparticles-based vaccines for COVID-19
Nature Nanotechnology (2022)
-
The need for improved methodology in protein corona analysis
Nature Communications (2022)
-
Nanodelivery of nucleic acids
Nature Reviews Methods Primers (2022)
-
Reanalysis: the forgotten sibling of reproducibility and replicability
Nature Reviews Methods Primers (2022)